Researchers have shown that hair loss in women can be linked to lower levels of IGF1, a growth factor secreted by the dermal papilla. IGF1 promotes cell multiplication in the bulb and normalizes the hair cycle. In ex-vivo tests, Keranat™ significantly increases the secretion of IGF1, thereby increasing cell proliferation in the bulb.
Cell Proliferation in the Hair Bulb
Keranat™ significantly stimulates cell proliferation in the bulb by 140%, which is a good indicator of optimal hair growth.
Hair Anchoring
Keranat™ increases the thickness of collagen in the connective tissue around the hair follicle, which improves hair anchoring.
Reduction of Hair Loss
After 12 weeks, Keranat™ significantly reduces hair loss compared to a placebo. This average reduction of 50% was measured using a recognized objective method: the phototrichogram. Additionally, 91% of women observed a reduction in hair loss (self-assessment).
After 6 weeks, a dermatologist noted that the hair of subjects consuming Keranat™ was more beautiful and shinier. After 12 weeks, the hair is significantly more beautiful and shinier with Keranat™ compared to placebo. Also, after 12 weeks, 75% of women noticed their hair was shinier, softer, and more flexible.
Reduced Scalp Dryness
After 6 weeks, a dermatologist noted that the scalp is less dry in subjects consuming Keranat™. After 12 weeks, Keranat™ significantly reduces scalp dryness compared to placebo.
S. Boisnic et al, Hair Therapy and Transplantation, 2016
« Miliacin associated with polar lipids : effect on growth factors excretion and extracellular matrix of the dermal papilla hair follicle model maintained in survival conditions »